Presentation at the 2012 PAGE 21st Annual Meeting

RNS Number : 8965E

Physiomics PLC

07 June 2012

 



Physiomics plc

 ("Physiomics" or "the Company")

Physiomics to present on the new R&D development at the 2012 PAGE 21^st Annual meeting

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the PAGE 21^st annual meeting, taking place at the Palazzo del casino, Venice Lido, Italy on 06-08 June 2012.  Dr Eric Fernandez, Project Leader at Physiomics, will present on an updated version of an anti-cancer drug combination and regimen database; and Dr Frances Brightman, Senior Scientist at Physiomics, will present the application of the Virtual Tumour platform to three-dimensional cell cultures.

This database of anti-cancer drugs and therapeutic treatment information is aimed at researchers in oncology and clinicians. Accessible through a web interface, it provides data on more than 130 anti-cancer drugs, on drug combinations and also on several hundred cancer chemotherapy regimens routinely used in the clinic. 

We are also investigating the use of 3D cultures to further reduce the need for animal study data to calibrate our models. The results presented in the poster illustrate how the Virtual Tumour could be used to predict the out come of xenografts study base on such 3D culture experiments.

The first abstract ("Predicting in vivo drug response and synergistic combinations from three -dimensional tumour cell cultures") and the second abstract ("A database of PK/PD parameters and information for the modelling of anti-cancer drugs regimen and combination") will be both presented in the third poster session, scheduled 10.05 AM - 11:35 AM, 07 June 2012.

More information about the conference may be found at: www.page-meeting.org

Contacts:

Physiomics Plc

Dr Christophe Chassagnole, Chief Operating Officer, [phone]

WH Ireland Limited

Katy Mitchell, [phone]

 

END

 

 

NRASSFFSWFESELM